Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.
CITATION STYLE
Pinato, D. J., Guerra, N., Fessas, P., Murphy, R., Mineo, T., Mauri, F. A., … Rimassa, L. (2020, April 30). Immune-based therapies for hepatocellular carcinoma. Oncogene. Springer Nature. https://doi.org/10.1038/s41388-020-1249-9
Mendeley helps you to discover research relevant for your work.